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Abstract: HIF-1 is a master regulator of oxygen homeostasis involved in different stages of cancer 
development. Thus, HIF-1 inhibition represents an interesting target for anti-cancer therapy. It 
was recently shown that HIF-1 interaction with NQO1 inhibits its proteasomal degradation, thus 
suggesting that targeting the stability of NQO1 could led to destabilization of HIF-1 as a 
therapeutic approach. Since the molecular interactions of NQO1 with HIF-1 are beginning to be 
unraveled, we review here our current knowledge on the intracellular functions and stability of 
NQO1, its pharmacological modulation by small ligands, and the molecular determinants of its 
roles as a chaperone of many different proteins including cancer-associated factors such as p53 and 
p73. This knowledge is then discussed in the context of potentially targeting the intracellular 
stability of HIF-1 by acting on its chaperone, NQO1. This could result in novel anti-cancer 
therapies. 
Keywords: HIF-1;NQO1; hypoxia; angiogenesis; cancer; protein:protein interactions; ligand 
binding; proteasomal degradation  
 
1. HIF-1: structure, function, regulation and disease 
Oxygen homeostasis is one of the main principles of life for most organisms, especially metazoa. 
The availability of oxygen regulates many physiological processes that are strictly controlled by a 
complex network of molecules in the organism. In metazoa, the master transcription factor that 
supervises this regulatory network is the Hypoxia-induced factor 1 (HIF-1). HIF-1 regulates the 
expression of a multitude of genes in response to oxygen availability and plays a fundamental role in 
many physiological and pathological processes  [1, 2]. 
 
1.1. HIF-1  structure and function 
HIF-1 is a DNA-binding complex composed of two subunits (α and β), both basic 
helix-loop-helix (bHLH) proteins of the PER-ARNT-SIM (PAS) family. HIF-1β (initially named aryl 
hydrocarbon nuclear receptor translocator, ARNT) is constitutively expressed, and thus, its 
expression and activity are oxygen-independent. In contrast, HIF-1α is strongly repressed in 
normoxia and induced in hypoxia  [3]. In response to low oxygen, both subunits of HIF-1α dimerize, 
and HIF-1 binds to the hypoxia response element (HRE) of the promoter or enhancer region of the 
target genes to induce transcription. HIF-1 induces the transcription of numerous genes  [4, 5] 
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involved in many biological processes, such as angiogenesis, erythropoiesis, anaerobic metabolism, 
cell survival, and cell proliferation. Thus, it is crucial for cancer development (see Section 1.3). 
 
 
Figure 1. Structure and regulation of HIF-1α. (A) Schematic representation of human HIF-1α and 
H1β structure. Both proteins form part to HLH–PAS transcription factor family and contain a 
N-terminal bHLH domain (implicated in DNA binding) and two PAS domains (responsible of its 
dimerization). HIF-1α contains an oxygen-dependent degradation domain (ODDD) that mediates 
oxygen-regulated stability, and two transactivation domains (TAD), that mediate its transcriptional 
activity and its stability. (B) In normoxia, HIF-1α is subjected to oxygen-dependent hydroxylation 
by PHD hydroxylases, conducting HIF-1α to ubiquitination by the pVHL and proteasomal 
degradation. MDM2/p53 are also involved in ubiquitination and degradation of HIF1A protein in 
the VHL‐independent manner. Under low oxygen levels (as well as some metabolites of TCA cycle) 
PHD is inhibited, HIF-1α translocates to the nucleus and promotes the activation of target genes. 
Transactivation of HIF-1α could be also induced by PI3K/MAPKs signaling pathways upon 
activation of some growth factor, hormones and cytokines. 
 
The basic domain and the carboxy-terminus of PAS are specifically required for DNA binding 
of HIF-1 to the HRE DNA sequence 5V-RCGTG-3V, whereas the HLH domain and the 
amino-terminus of the two subunits of PAS proteins mediate their dimerization  [6]. In addition to 
ubiquitous HIF-1α and HIF-1β, both subunits exist as a series of isoforms encoded by distinct 
genetic loci with different splice variants  [7, 8, 9, 10]. HIF-1α constitutes the most prominent 
member of the three HIF-1α subunits in the human genome. The most important structural elements 
of HIF-1α are summarized in Figure 1A. HIF-1 has two nuclear location sequences (NLS) at the 
amino (residues 17-74) and carboxyl (residues 718-721) ends of the protein  [11]. The stability of the 
protein is mainly regulated at the oxygen dependent degradation domain (ODDD). This domain 
contains two peptide sequences rich in proline (P), glutamic acid (E), serine (S), and threonine (T) at 
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residues 499-518 and 581-600  [3]. PEST-like motifs are present in short-lived proteins rapidly 
targeted for intracellular degradation. They mediate HIF-1 degradation by the ubiquitin-proteasome 
pathway  [12, 13]. HIF-1 also contains two transactivation domains, N-TAD (residues 531-575) and 
C-TAD (residues 786-826)  [14]. Under hypoxia several co-activators such as CBP/p300/SRC-1 
interact with the C-TAD inducing HIF-1 transcriptional activity, while N-TAD is responsible for 
stabilizing HIF-1α against degradation  [15].     
 
1.2. Regulation of HIF-1  expression, protein levels and transcriptional activity 
Although HIF-1 is tightly regulated at the transcriptional, translational and posttranslational 
levels  [4], protein degradation plays a dominant role in regulating its activity.  
1.2.1. Oxygen-dependent regulation 
Most of HIF-1 regulation is mediated by the HIF-1α subunit. Under normoxic conditions, 
HIF-1α protein is constitutively synthesized and rapidly targeted for ubiquitination and 
proteasomal degradation, thus keeping minimal steady-state levels. In this scenario, HIF-1α 
becomes hydroxylated by members of the prolyl hydroxylase domain (PHD) family on two specific 
prolines (P402 and P564) of the ODDD and NTAD domains, respectively  [16, 17, 18]. Hydroxylation 
of these proline residues generates a binding site for an E3-ubiquitin ligase complex that contains the 
von Hippel Lindau protein (pVHL), elongin B (ELB), elongin C (ELC), cullin 2 (CUL2), and ring box 
protein 1 (RBX1). As a result, HIFα is polyubiquitinated and degraded by the proteasome  [19, 20, 21, 
22] (Figure 1A).  
In addition to this oxygen-dependent regulation of HIF-1α stability, oxygen affects DNA 
binding and transcriptional activity as well. This effect is mediated by the factor inhibiting HIF-1 
(FIH-1), an asparagyl hydroxylase that catalyzes the hydroxylation of Q803 within the C-TAD 
domain of HIF-1α. Hydroxylation of Q803 leads to a steric clash that prevents the binding of the 
p300 and CBP coactivators to HIF-1α, abolishing their transactivation  [23].  
In hypoxia, impaired hydroxylation of HIF-1 allows dimerization of the transcriptional 
complex and the subsequent expression of its target genes. The mitochondrial electron transport 
chain (MEC) consumes the vast majority of cellular oxygen and may play an important role in 
HIF-1α regulation by determining the amount of oxygen available to PHD enzymes  [24, 25, 26]. In 
this sense, pharmacological or genetic inhibition of mitochondrial respiration may prevent the 
accumulation of HIF-1α in hypoxia  [27, 28]. However, there are other ways in which mitochondria 
affect the stability of HIF-1α (Figure 1B). Thus, in addition to requiring 2-oxoglutarate as a 
co-substrate, several metabolites of the tricarboxylic acic (TCA) cycle, especially succinate and 
fumarate, inhibit the HIF hydroxylases  [26, 29, 30, 31]. In addition, reactive oxygen species 
produced by MEC in hypoxia also increase the stability of HIF-1α  [27, 32, 33, 34, 35]. 
1.2.2. Growth factor signaling pathways 
HIF1 is induced by numerous stimuli other than hypoxia, including growth factors, cytokines 
and hormones  [36, 37, 38, 39, 40, 41]. These signals lead to the activation of mTOR (by PI3K/AKT) 
and the mitogen activated protein kinases (MAPK) (by the RAS/RAF/MEK/ERK kinases cascade) 
which can phosphorylate 4E-BP1 favoring cap-dependent translation of HIF-1α mRNA  [42, 43, 44]. 
MAPKs also play an important role in the regulation of the transactivation activity of HIF-1. Once 
activated, members of this family phosphorylate HIF1α, enhancing the binding of the coactivator 
p300/CBP  [43, 45]. 
1.2.3. The Mdm2 pathway 
A complex interplay exists between p53 and HIF-1α. On one hand, HIF-1α binds to Mdm2 (the 
mouse's double minute 2 homologue), inhibiting Mdm2-dependent degradation of p53  [46]. On the 
other hand, p53 also mediates HIF-1α activity. In this sense, at moderate expression levels, p53 
competes with HIF-1α for p300, consequently decreasing the transcriptional activity of HIF-1α. 
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Moreover, high levels of p53 expression lead to HIF-1α degradation  [47]. This is due to binding of 
p53 to HIF-1α that allows Mdm2-mediated ubiquitination of HIF-1α and its proteasomal 
degradation [48] (Figure 1B).  
1.2.4 Heat shock protein 90 (Hsp90) 
HIFα stability is also regulated by other signaling pathways, such as Hsp90 inhibitors that 
promote HIFα degradation in a pVHL-independent manner  [49, 50]. In addition, Hsp90 is known 
to bind directly with HIF-1α inducing some conformational changes in its structure to fit and couple 
with HIF-1β initiating its transactivation  [51] (Figure 1b). 
 
1.3. HIF-1  in cancer 
Cancer is defined as the autonomous growth and spread of a clone of somatic cells, under 
selective pressure, which is able to use multiple cellular pathways to modify its environment in 
favor of its own proliferation and against the needs of the organism, escaping physiological 
constraints on cell growth, including immune surveillance  [52].  
As the cell clone grows, its core becomes further removed from the blood supply and changes in 
oxygen availability are key for tumor cells to reorganize their metabolism in order to match oxygen 
supply with cellular demands. Thus, hypoxia becomes one of the key features of tumor 
microenvironment  [53], a fact first reported in early studies where hypoxic cells were shown to 
surround the necrotic center in histological sections of lung carcinomas  [54] and later demonstrated 
in essentially all solid tumors (reviewed in  [53]). Intratumoral hypoxia is widespread and almost 
independent of tumor size, grade, stage, or histology  [55]. Numerous studies have elucidated the 
molecular mechanisms involved in the cellular response to hypoxia, and three leaders in the field 
have been awarded recently the Nobel Prize in Medicine for their achievements, including their 
seminal work on HIF-1α, a critical transcription factor for adaptation to hypoxia  [56, 57] 
(https://www.nobelprize.org/prizes/medicine/2019/summary/). 
HIF-1α regulates a number of physiological pathways involved in cancer, such as cell 
proliferation, survival, apoptosis, angiogenesis, glucose metabolism, immune cell activation and 
stem cell regulation  [56, 58]. In particular, HIF-1α plays an important role in at least two of the main 
biological capabilities acquired during the multistep process of tumor development (the "hallmarks" 
of cancer,  [52]): reprogramming cell metabolism and inducing angiogenesis.   
1.3.1 Role of HIF in reprogramming cancer cell metabolism 
When oxygen is available to mammalian cells, MEC and oxidative phosphorylation allow the 
highest yield of ATP from glucose, but many tumor cells choose oxygen-independent glycolysis 
even in normoxia conditions ("aerobic glycolysis" or Warburg effect) to extract smaller amounts of 
ATP but also valuable metabolites essential for the rapid growth of neoplasms  [59]. Reaching this 
"sweet spot" of optimal utilization of glucose that maximizes cell growth requires a well-coordinated 
rearrangement of cell metabolism. Although HIF-1α has long been recognized as a key player in 
response to hypoxia, hypoxia-independent mechanisms for HIF-1α signaling have also been recently 
reported when oxygen is available to the cell (“pseudohypoxic” conditions)  [60].  
Reviewing the number of cancer types where HIF-1α is part of the oncogenic process exceeds 
the aim of this article. In the recent Pancancer analysis of more than 2500 cancer genomes, VHL, a 
tumor suppressor gene (TSG) and the key regulator of HIF-1α, was among the most commonly 
mutated TSGs, following the highly prevalent TP53, CDKN2A/B, PTEN and SMAD4  [61]. Given its 
historical relevance, we will center this review on renal cancer, a type of malignancy that was central 
to the understanding of the role of hypoxia, angiogenesis and metabolism in cancer  [62]. The study 
of hereditary cancer syndromes was, like in other examples of TSGs, crucial to the discovery of the 
mechanism of disease involving VHL. VHL (von Hippel-Lindau) family members carrying 
loss-of-function (LoF) mutations at the VHL gene are predisposed to kidney cancers. In particular, 
carriers display an autosomal dominant risk for clear cell–type renal cell carcinoma (ccRCC) in 
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addition to other health problems  [63]. Moreover, another type of RCC, named papillary-type 2 
RCC, where VHL mutations are not involved, is known to harbor mutations in the gene for 
Fumarate Hydroxylase (FH), an enzyme of the TCA cycle. These mutations deregulate HIF 
expression also, underscoring the important role of angiogenic and metabolic responses in renal 
carcinoma.  
LoF mutations at VHL are observed in a majority of ccRCC, interfering with HIF-1α 
degradation and promoting a pseudohypoxic metabolic reprogramming of cancer cells. Stabilized 
HIF-1α translocates to the nucleus, where it dimerizes with HIFβ and upregulates transcription of 
genes related to cellular metabolism, reprograming it towards aerobic glycolysis by increasing 
conversion from pyruvate to lactate (via upregulation of LDHA) and by blocking pyruvate 
conversion to acetyl-CoA by PDH (via upregulation of PDK1). Stable HIF also increases 
transcription of transporters for nutrients such as glucose and glutamine, ultimately enhancing the 
glycolytic and reductive carboxylation pathways, respectively  [64]. In addition, HIF suppresses 
aerobic respiration by increasing levels of BCL2-related BNIP3 and BNIP3L, which leads to 
mitochondrial autophagy  [65, 66]. HIF also interferes with aerobic respiration via microRNAs, such 
as miR-210, which disrupts Fe-S clusters necessary for the MCE  [67]. Another important 
consequence of HIF stabilization in cancer is that, by upregulating the expression of glycolytic 
enzyme pyruvate kinase M2 (PKM2), it amplifies its own transcriptional activity, resulting in a 
positive-feedback mechanism  [68]. 
1.3.2 Role of HIF in cancer neoangiogenesis 
The capability to induce abnormal vascular growth that ensures abundant supply of nutrients is 
another important hallmark of cancer and it has been one of the most successful targets of modern 
cancer therapy  [52]. Neoangiogenesis is particularly conspicuous in renal cell carcinoma and 
prominent vascular remodeling as been linked to HIF disregulation as a consequence of VHL 
mutations  [69]. The key molecular event in tumor angiogenesis is the increase in Vascular 
Endothelial Growth Factor (VEGF)-A induced by the hypoxia resulting from tumor growth but also 
from mutations in the HIF pathway  [70]. Many other factors are involved in blood vessel growth in 
tumors  [71]. These complex angiogenesis patterns and disregulation of vessel stabilization and 
maturation have been also well documented in renal carcinoma  [72].  
1.3.3 Association of HIF-1 expression and cancer prognosis 
Although the complexities of cancer prognosis (the high variability of tumor mutations, 
histological types, grades and stages) makes it too simplistic to think that the levels of expression of a 
single gene such as HIF1A might have significant impact on prognosis, increased HIF-1α and HIF-2α 
protein levels in diagnostic tumor biopsies have been correlated with poor prognosis in other types 
of cancer also, such as brain, breast, colon, cervix, endometrium, head/neck, lung, ovary, pancreas, 
prostate, rectum and stomach (reviewed in  [1]). More recently, high HIF-1α expression has been 
studied in triple-negative breast cancer (TNBC)  [73]. TNBC are a heterogeneous group of poorly 
differentiated, highly aggressive and metastatic breast cancer type. They lack specific 
molecular-targeted therapy and there is an urgent need to find effective biomarkers rather than 
relying of their lack of hormone receptors and Her2 expression to define this subgroup. These 
authors  [73] found that HIF-1α and c-Myc expression detected by immunohistochemistry could 
add to the development of a prognostic nomogram including histological grade and stage of cancer 
(based on tumor size (T), lymph node involvement (N) and distant metastases (M), known as TNM 
status). In an effort to validate the proposed nomogram in our institution, we are currently 
evaluating the feasibility of including HIF-1α immunohistochemistry in the biomarker profile 
(Figure 2). As a transcription factor induced in tumor cells by hypoxic environmental stress, HIF-1α 
could regulate a variety of downstream genes, thereby increasing the invasive ability of tumors and 
their resistance against standard radiotherapy and chemotherapy.  
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Figure 2. Nuclear HIF-1 expression (brown staining) in clear cell renal carcinoma. Common 
deletions of the VHL gene result in lack of HIF1 degradation, with the subsequent activation of HIF1 
as a nuclear transcription factor that drives tumor cell proliferation. 
2. NQO1 as a protein chaperone: current knowledge and potential application to target 
HIF-1 stability   
The recent description of NQO1 as a protein chaperone protecting HIF-1 against 
degradation  [74] supports that targeting this protein-protein interaction (PPI) could allow 
inactivation of HIF-1. Since our knowledge on this particular PPI is very limited, in this section we 
will describe a wealth of information available for the activity and stability of NQO1, focusing on 
what we know on other PPI by which NQO1 acts as a chaperones and how small ligands and 
missense mutations are capable of modulating these PPI. 
 
2.1. Overview of NQO1 expression, regulation and functions: on the potential roles of O2 levels and HIF-1 
NAD(P)H quinone oxidoreductase 1 (NQO1; DT-diaphorase; EC 1.6.5.2) functions as a 
homodimer of 31 kDa subunits  [75, 76]. Each subunit contains two domains: an N-terminal domain 
(NTD, comprising approximately residues 1-225), that binds tightly one molecule of FAD and is 
capable of folding and assembly into dimers autonomously, and a C-terminal domain (CTD, 
comprising the last 40-50 residues) that completes the monomer:monomer interface and the binding 
sites of NAD(P)H and the substrates (Figure 3A) [75, 77, 78, 79, 80, 81]. Its main enzymatic function is 
to catalyse the two electron reduction of quinones, thus avoiding the production of reactive, and 
potentially cytotoxic, semiquinones (Table A1)  [82]. Since one of its substrates is menadione 
(vitamin K3) it can function in blood clotting, although its role appears to be minor compared to 
vitamin K oxidoreductase  [83]. Other substrates include α-tocopherol-quinone and ubiquinone, 
which are maintained in their reduced (antioxidant) forms by the enzyme  [84, 85]. NQO1 can also 
catalyse the reduction of superoxide radicals and thus plays a role in directly protecting the cell from 
reactive oxygen species  [86]. The enzymatic cycle of NQO1 follows a ping-pong mechanism with 
two main steps or semireactions (Figure 3B): in a first one, NAD(P)H binds to the holo-form 
(NQO1holo) of the enzyme (FAD is not released during the cycle), consequently reducing the flavin to 
FADH2 and releasing NAD(P)+. This reductive half-reaction is extremely fast, with a rate constant in 
the range of 109 M-1·s-1. Importantly, the rate of this reductive half-reaction is strictly 
NADH-dependent, and thus, should be accelerated due to the HIF-mediated enhancement of 
aerobic glycolysis (raising cytosolic NADH levels, section 1.3.1); in a second and slower step (with a 
rate constant of 105-106 M-1·s-1), the oxidative half-reaction, the substrate binds and is reduced by the 
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FADH2, thus releasing the reduced substrate and regenerating the holo-enzyme  [76, 79]. 
Dicoumarol, a potent anticoagulant and mitochondrial uncoupling agent, acts as a competitive 
inhibitor of NAD(P)H during the NQO1 cycle (Table A1)  [87].  The high level of NQO1 expression 
in some cancer cells, coupled with its role in defence against ROS, has led to the suggestion that 
NQO1 inhibition may be a novel therapy for the disease. Dicoumarol is an effective inhibitor of 
pancreatic cancer cells in culture, but no NQO1 inhibitors are yet in clinical use  [88].  
 
Figure 3. Structure and enzymatic cycle of NQO1. (A) Three-dimensional structure of NQO1dic (with 
FAD and dicoumarol bound)(PDB ID 2F1O). The N-terminal (NTD) and C-terminal (CTD) domains 
are indicated. MMI stands for the monomer:monomer interface. (B) Schematic representation of the 
catalytic cycle of NQO1. 
The NQO1 protein has also non-enzymatic functions in which it mostly participates in PPI, 
mediating the stability of its binding partners (Figure 4 and Table A2). Indeed, and as we will further 
discuss in sections 2.2 and 2.3, several of the ligation states populated of NQO1 during the catalytic 
cycle (NQO1holo, either oxidized and reduced, or the dead-end complex of the holo-enzyme with 
dicoumarol, NQO1dic) are very relevant to the discussion of PPIs developed by NQO1.   
NQO1 is also known to undergo different post-translational modifications (PTMs), some of 
which have been characterized in a site-specific manner revealing that these modulate NQO1 
function and stability in different manners. Phosphorylation of NQO1 at T128 by the kinase Akt 
results in polyubiquitination and degradation of NQO1 via the proteasome  [89]. A 
phosphomimetic mutation on S82 showed reduced FAD binding affinity and consequent loss of 
intracellular protein stability, although the kinase involved in this phosphorylation event has not 
been identified yet  [90]. Consequently, phosphorylation of NQO1 at different sites may have an 
impact on the intracellular stability of its protein partners through destabilization of NQO1.  
NQO1 is expressed in most human cell types 
(https://www.genecards.org/cgi-bin/carddisp.pl?gene=NQO1) and its expression can be 
upregulated in response to stress. Two control elements are located upstream of the human NQO1 
gene – the antioxidant response element (ARE) and the xenobiotic response element (XRE)  [91, 92, 
93, 94]. A key regulator of the ARE is nuclear factor erythroid 2-related factor 2 (Nrf2). This 
transcription factor from the basic leucine zipper family is located in the cytosol under non-stressed 
conditions. Here it interacts with Kelch like-ECH-associated protein 1 (KEAP1) that targets it for 
ubiquitin-mediated proteasomal degradation  [95, 96].  Oxidative stress is sensed by the oxidation 
of disulphide bonds in KEAP1  [97]. This releases Nrf2, which translocates to the nucleus and, 
together with members of the small musculoaponeurotic fibrosarcoma protein family (sMaF), binds 
to AREs  [98]. This results in the recruitment of the Mediator complex, the acetylation of Nrf2 and 
the activation of a range of genes involved in antioxidant defense, including NQO1  [99, 100, 101]. 
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Nrf2 also upregulates genes for NADPH generation, thus ensuring that enzymes like NQO1 have 
sufficient reduced cofactor  [102, 103]. The ARE also responds to some antioxidants (e.g. resveratrol 
and quercetin), by upregulating the expression of NQO1 and other antioxidant enzymes  [104, 105]. 
Interestingly, the ARE that controls the expression of NQO1, is also activated by hypoxic 
conditions  [106]. Thus, NQO1 protein levels increase under hypoxic conditions  [107]. 
Consequently, NQO1 is overexpressed in tumours due to their hypoxic environment. 
 
Figure 4. The NQO1 interactome. (A) NQO1 protein partners described in at least one report. (B) 
Connectivity between NQO1 partners. The shorter the radial distance between a partner and NQO1 
indicates a higher interconnectivity. Partners in yellow are from mouse and in blue from human. (C) 
A zoom from panel B shows the most highly interconnected partners of NQO1. (F-J) Interactions 
between NQO1 partners in panel C and other proteins to highlight their different interconnectivity. 
The thickness of connecting yellow lines is related to the number of reports describing the interaction. 
Data were retrieved from the BioGRID database (https://thebiogrid.org/108072)  [108]. 
The XRE is activated by the aryl hydrocarbon receptor (AhR), a basic helix-loop-helix 
transcription factor. The protein binds to a wide range of hydrophobic xenobiotics and translocates 
to the nucleus in response. Here it heterodimerises with aryl hydrocarbon nuclear translocator 
(ARNT or HIF1β) and binds the XRE  [109, 110]. In the case of the NQO1 gene, AhR at the XRE and 
Nrf2 functionally cooperate to regulate its expression  [111]. Like the ARE, the XRE can be induced 
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by hypoxia  [112].  Although HIF-1α also partners with HIF1β to regulate transcription, siRNA 
silencing of the HIF1α gene does not affect NQO1 expression  [113]. This suggests that HIF1α is not 
directly involved in regulating NQO1 expression. 
 
2.2. NQO1 macromolecular interactions 
To date, there are 47 protein partners of NQO1 compiled in the BioGRID database 
(https://thebiogrid.org/108072)  [108]. This set includes 33 human proteins (actually one is a 
pseudo-gene product). The remaining 14 are from rodents and belong to different subunits of the 
20S proteasome (Figure 4A). In addition, NQO1 can interact specifically with certain RNAs 
modulating their expression  [114]. Focusing on protein partners, there is certain evidence within 
the NQO1 interactome supporting that different partners (i.e. nodes) of this network can interact not 
only with NQO1 but also among each other, Consequently, this could generate regulatory circuits 
upon interaction of different partners in two- or multiple-way manners (i.e. binary, ternary, 
quaternary….complexes; Figure 4B). This also suggests that we may affect the properties (e.g. 
intracellular activity or stability) of one node by targeting different adjacent nodes in the network, an 
effect that could be amplified particularly in nodes with high connectivity. The most representative 
and consistently reported nodes with such a high connectivity for NQO1 are shown in Figure 4C and 
Table A2. Importantly, HIF-1 belongs to this group.  
A critical reason for better understanding the interactome of NQO1 emerges from a well-known 
consequence on its interaction with partners: it leads to changes in the stability of the partner against 
(Ub-dependent or –independent) proteasomal degradation. Thus effects on the intracellular levels of 
NQO1 or in the strength of its interaction with partners may translate into altered stability of the 
nodes in the interactomic network. For instance, reducing the availability of the FAD precursor 
riboflavin leads to increased population of the flavin-free NQO1apo state, which is very sensitive to 
proteasomal degradation through ubiquitin-dependent and -independent mechanisms  [115, 116]. 
This is in part caused by the destabilization of the CTD of NQO1 in the absence of bound FAD that 
promotes its ubiquitination and degradation  [116]. Remarkably, addition of the inhibitor 
dicoumarol does not stabilize the NQO1 protein intracellularly but seems to reduce its ability to 
interact with and stabilize these protein partners (see Table A2). Binding of NAD(P)H, which 
reduces the bound flavin cofactor, seems to enhance the interaction of NQO1 with these protein 
partners ( [117], Table A2). A recent study also suggested that NQO1 with a reduced flavin cofactor 
could be a physiologically important state in the cell  [118], and thus very relevant to understand the 
interactome dynamics of NQO1 (note that the population of this state can be promoted due to 
HIF-mediated increased levels of cytosolic NADH, section 1.3.1). Additional factors modulating 
NQO1 intracellular stability, such as protein phosphorylation events, small ion binding or single 
amino acid changes  [119, 120, 121, 122, 123], may thus propagate and amplify these effects to the 
stability of the NQO1 protein partners. 
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Figure 5. Subcellular location of NQO1 interacting human partners based on data from GeneCards® . 
For all the interactors, the subcellular compartment (location) and its confidence (1-5, from the lowest 
to the highest) were retrieved from GeneCards® . (A) Accumulated score for each organelle as the 
sum of the numerical degree of confidence for all partners found in a given compartment. The 
highest accumulated score (i.e. for the nucleus) was used to normalize yielding the Score. As Fraction, 
we refer to the fraction of all the partners found in a given organelle. Note that the ratio 
Score:Fraction gives a measure of the degree of confidence for finding a given partner in a given 
subcellular location. (B) Subcellular location of NQO1 partners in the three subcellular locations of 
NQO1 reported with confidence (i.e. equal or higher than 3) as the fraction of the total of NQO1 
partners. Overlapping regions in the Venn diagram reveal the presence of an NQO1 partner in at 
least two subcellular locations.  
Another critical issue for understanding the interaction of NQO1 with its partners and 
subsequent effects of these interactions on the stability of its interactome is the subcellular location of 
NQO1 and its partners. It is generally accepted that NQO1 subcellular location is primarily cytosolic, 
where it can fulfill its roles as antioxidant/detoxifiying enzyme and is able to interact with protein 
and RNA partners. However, there is also certain evidence supporting its location in other 
subcellular compartments, mostly mitochondria and the nucleus (with low confidence in other 
organelles)(Figure 5A; GeneCards® ; 
https://www.genecards.org/cgi-bin/carddisp.pl?gene=NQO1&keywords=NQO1). Importantly, most 
of the protein partners of NQO1 also seem to primarily localize in the nucleus and the cytosol, and to 
a moderate extent in the mitochondria, cell membrane and extracellularly, apparently coexisting 
between more than one subcellular location (Figure 5A-B). In the case of the cytosol and the nucleus, 
about 50% of NQO1 partners may operate in any of these locations and translocate between these 
two to fulfill their roles in cytosolic and nuclear processes such as control of DNA expression (p53, 
HIF-1  c-FOS, NRF-2, NME1, FUBP3), regulation of RNA and translation (POLDIP3, 
YTHDF1, NXF1, MOV10, DAZAP1, RPS19), regulation of nuclear protein function (PARP1 and 
TRIM25), protein folding and degradation (BAG-3, eIF4G1, DCAF15, HSPA4, STUB1, UBE2D1). In 
addition, a number of metabolic enzymes in the cytosol and mitochondria (ODC, NDUSF7, NME1, 
ADK, GOT1, AK4) could also interact with NQO1 in these compartments. Indeed, NQO1 
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overexpression in mice is known to enhance glycolytic and mitochondrial respiration activities and 
enhance metabolic flexibility, mimicking the beneficial effects of caloric restriction  [124]. It is worth 
noting that the proteasomal protein degradation machinery may operate through rather similar 
mechanisms in the cytosol and the nucleus  [125, 126], and thus, the well-known chaperone role of 
NQO1 for different protein partners (see Table A2), may indeed operate in the cytosol thus 
increasing the levels of cytosolic proteins amenable to import to other organelles (such as nucleus or 
mitochondria;  [74, 127]) and plausibly by stabilizing these proteins upon import of both the partner 
and NQO1 in these organelles. Noteworthy, although more rarely described, the presence of NQO1 
in other subcellular locations such as cytoskeleton may explain other roles of the multifunctional 
NQO1 protein. For instance, recent studies have supported that NQO1 may provide an adequate 
supply of NAD+ for deacetylase activity of different sirtuins associated with microtubule 
dynamics  [118, 124, 128]. These studies also highlight the potential plasticity of NQO1 subcellular 
location during different cellular conditions or stages (e.g. the recruitment of cytosolic NQO1 to 
cytoskeletal structures during cell division  [118]). 
 
 
Figure 6. Structure and dynamics of NQO1 upon binding different ligands. (A) Structural overlay of 
the X-ray structures of NQO1holo (1D4A), NQO1holo:NAD+ (kindly supplied by Profs. Mario Bianchet 
and Mario Amzel, John Hopkins University Medical School, Baltimore, USA) and NQO1dic (2F1O). 
The lower panel shows a zoom highlighting the position of the FAD (orange, NQO1dic and red, 
NQO1holo:NAD+), NAD+ and dicoumarol (Dic). (B) Dicoumarol binding causes long-range effects on 
the structural dynamics of NQO1 WT. Residues shown in dot representation are those for which the 
structural dynamics is reduced according to HDXMS  [129]. (C) Most of the residues whose 
dynamics is reduced upon dicoumarol binding are solvent-exposed. The plot in the right shows the 
solvent accessible surface area (SASA) for the each residue as calculated in  [129] and colour circles 
indicate the magnitude of the change in structural dynamics. The figure on the left shows the 
structural location of solvent-exposed residues (SASA > 20%). The color scales in panels B and C 
reflect the magnitude of the changes in protein dynamics according to  [129] and red arrows indicate 
the position of dicoumarol. 
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2.3. Changes in NQO1 stability, structure and dynamics upon ligand binding: implications for the stability of 
its protein partners 
The functional chemistry of NQO1 is remarkably complex. At least four different ligation states 
(with small molecules bound) are relevant to understand the intracellular stability and enzymatic 
activity of NQO1 as well as its effects on the function and stability of its macromolecular partners: i) 
NQO1apo, which has no ligand bound; ii) NQO1holo, which contains a molecule of oxidized FAD per 
NQO1 monomer; iii) NQO1holo-red , containing the FAD cofactor reduced upon interaction with 
NAD(P)H and hydride transfer; and iv) NQO1dic, a ternary complex of NQO1holo with the inhibitor 
dicoumarol bound.  These different ligation states interact differently with NQO1 protein 
partners  [78, 117, 127]. High-resolution structural models for these complexes are, to the best of our 
knowledge, not reported. Thus, we will focus in this section on the structural and dynamic 
consequences of ligand binding to NQO1 in an attempt to obtain some insight into their regulatory 
effects on NQO1 interactions with protein partners (always from an NQO1 point of view). 
NQO1apo exists as a stable and expanded dimer characterized by significantly large 
conformational flexibility  [76, 78, 79, 80, 119, 130, 131, 132]. Although no high resolution structural 
model is available for this state, recent kinetic studies using hydrogen-deuterium exchange mass 
spectrometry (HDXMS) have identified a minimal stable core that holds the protein dimer while 
most of the protein exists forming a highly dynamic structural ensemble, including the FAD and 
substrate binding sites in non-competent states for binding  [129]. This remarkable conformational 
flexibility makes NQO1apo likely the most relevant state to understand the intracellular stability of 
NQO1, since the flexible CTD acts as initiation site for rapid degradation through 
ubiquitin-dependent and -independent proteasomal pathways  [90, 116]. It is plausible that this 
unstable and highly dynamic NQO1apo state is not capable of interacting with NQO1 protein 
partners, or at least, does so with lower affinity  [78].  
Binding of FAD triggers a large conformational change leading to compaction of the protein 
dimer, increase in ordered secondary structure, overall conformational stabilization and a large 
decrease of protein dynamics that is sensed in almost the entire protein structure  [78, 79, 80, 119, 
129, 130, 131, 133]. This NQO1holo state is amenable for high-resolution structural studies [81](Figure 
6A). This state is also known to be intracellularly stable and likely to interact with protein partners 
quite efficiently  [115, 116, 117, 119, 123].  
Binding of NAD(P)H results in FAD reduction, leading to a state we named NQO1holo-red. This 
reaction is extraordinarily fast (close to the diffusion limit) and this state is likely unstable unless 
strongly reducing and/or anaerobic conditions are used (at least in vitro,  [79]). Consequently, 
detailed structural analyses on this state are non-existant. However, it is worth commenting on some 
studies carried out under less stringent (i.e. aerobic) conditions, particularly because a wealth of 
work support that generally, this state may strongly interact with NQO1 protein partners  [117, 127]. 
Using biochemical in vitro assays with NADP(H), it has been reported that NQO1holo-red influences 
the conformation of the CTD affecting the interaction with antibodies raised against it  [118] and 
apparently increasing the thermodynamic stability of this domain  [80, 118]. Intriguingly, the 
changes in conformation and stability of the CTD reported for NQO1dic and NQO1holo-red are 
strikingly similar, suggesting again that subtle differences in structure and dynamics between these 
two states are likely responsible for their opposing effects on the interaction of NQO1 with protein 
partners. 
Binding of dicoumarol (or NAD+) causes small structural rearrangements in the protein 
structure  [75, 78, 81, 131, 134](Figure 6A). Therefore, from NQO1 structural point of view, it is not 
straightforward to understand how NQO1dic prevents binding to or largely decrease binding affinity 
for macromolecular partners with subsequent effects on the stability of these partners  [78, 127]. An 
alternative explanation has emerged from studies on NQO1 protein dynamics by HDXMS  [129]. 
Binding of dicoumarol to WT NQO1 causes strong effects on NQO1 protein dynamics, affecting the 
local stability of the protein core and these effects propagate through long distances in the protein 
structure (Figure 6B). Some of these effects are sensed by the CTD (Figure 6B), which may explain 
how dicoumarol binding mildly increases the thermodynamic stability of this domain by about 1.5 
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kJ·mol-1  [80, 135]. Interestingly, a significant fraction of the residues whose stabilities are affected by 
dicoumarol binding appear on the protein surface and far from the ligand binding site (Figure 6C). 
This may imply that NQO1dic interacts differently with macromolecular partners through changes in 
the local stability and dynamics of the(se) binding site(s), which are likely located on NQO1 protein 
surface.  
2.4. Mutations and polymorphisms in NQO1. Disease and protein interactions 
The association of NQO1 activity with several human diseases with a huge social impact, 
particularly cancer, HIV infection and neurological and cardiovascular diseases, has attracted the 
attention towards the effects of naturally-occurring single amino acid changes on NQO1 and the 
predisposition provided by these changes towards disease  [76, 79, 116, 119, 122, 123, 130, 133, 136, 
137, 138, 139, 140, 141]. There are 106 missense variants described in human population (ExAC and 
gnomAD databases; 
https://gnomad.broadinstitute.org/gene/ENSG00000181019?dataset=gnomad_r2_1) and 47 missense 
variants in the COSMIC database 
(https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NQO1#variants). By far, the two most 
common single amino acid variants are p.P187S and p.R139W, with allelic frequencies in human 
population of about 0.25 and 0.03, respectively. Consequently, these two polymorphisms have been 
characterized in some detail. In addition, and to the best of our knowledge, only one other 
naturally-occurring single amino acid variant, p.K240Q (found in gnomAD and COSMIC databases), 
has been characterized. Since the studies aimed at characterizing the effects of these single amino 
acid variants have been recently reviewed  [76, 132], we will just outline in this section some of the 
key features described for them focusing on their potential impact on the interaction with protein 
partners and with those ligands known to modulate NQO1:protein interactions.   
The intracellular effects of p.P187S can be ascribed to changes in its stability and activity, 
respectively. This variant decreases by 10- to 40-fold the affinity for FAD thus promoting the 
population of NQO1apo  [79, 120, 122, 133, 136, 142]. Unlike WT NQO1, p.P187S in both NQO1holo 
and  NQO1apo are degraded similarly, due to a strong thermodynamic destabilization of the CTD in 
NQO1holo that triggers ubiquitination and degradation  [78, 79, 116, 119, 120, 122]. Remarkably, the 
crystal structure of p.P187S in the NQO1dic state is virtually identical to that of the WT enzyme  [79]. 
This seems to be paradoxical, because P187 is fully buried in the protein structure, close to the NQO1 
dimer interface and belongs to the minimally stable core of NQO1apo, and thus, a mutation to serine 
should have catastrophic effects on protein structure and function  [129, 136]. Detailed biochemical, 
biophysical, computational and mutational studies have shown that the effects of p.P187S are 
pleiotropic in the structure, function and stability of NQO1apo and NQO1holo, highlighting the critical 
role of propagation of the local stability effects due to p.P187S to long distances in the protein 
structure and affecting the dynamics and stability of critical regions of NQO1 function  [78, 79, 90, 
119, 120, 122, 131, 133, 136, 137]. These studies on p.P187S have also supported that different 
functional sites located far (over 10-20 Å ) in the structure are functionally and energetically coupled, 
and thus, we might modify the interaction of NQO1 with its partners by using an allosteric site (i.e. a 
ligand binding or mutated site) far from the protein:protein binding site. p.P187S is known to affect 
the interaction with NQO1 partners and lead to their destabilization, although it is not clear whether 
the origin of these alteration resides mainly in altered protein:protein interactions (i.e. binding 
affinity) or in the decreased intracellular stability of this variant that is reflected in those of the 
partners  [78, 115, 116, 119, 120, 123, 143].  
The polymorphism p.R139W represents a beautiful example in which a single nucleotide 
change may affect protein functionality at post-transcriptional and translational levels. In the one 
hand, it affects normal processing of NQO1 mRNA leading to exon 4 skipping, that produces a 
shorter version of the NQO1 protein that is extremely unstable inside cells due to the lack of part of 
the catalytic site (residues 102-139) critical for protein folding and stability  [144]. On the other hand, 
full-length NQO1 is also translated containing the single amino acid exchange p.R139W, which has 
only small effects on protein stability and function  [119, 130, 133]. Consequently, the former effect is 
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likely the prevalent one to explain the loss of intracellular NQO1 activity due to this 
polymorphism  [119, 130, 133, 144]. In addition, it must be expected that the decrease in full-length 
NQO1 protein caused by this polymorphism may negatively impact the stability of protein partners, 
although to our knowledge, no experimental evidence for this is available.  
The rare mutation p.K240Q was investigated to determine whether variable structural 
perturbations (mutations to glutamine as well as more perturbating variants such as changes to 
glycine and glutamate) in the CTD could propagate through the NQO1 structure to affect different 
functional sites  [122, 136]. K240 is a solvent-exposed residue involved in a highly-stabilizing 
electrostatic network in the CTD  [122]. This site accepted different types of mutations without 
compromising protein levels, activity, stability and solubility upon expression in E. coli.  [122, 136]. 
However, detailed biophysical and biochemical experimentation, actually revealed that the p.K240Q 
mutation affected locally the stability of the CTD, and this effect was more pronounced in the more 
perturbing in the mutations p.K240G and p.K240E  [122, 136]. A similar gradual effect was observed 
on the affinity for FAD, a remarkable result considering that the FAD binding site is located at 20 Å  
from the altered site  [122, 136]. Studies with this mutation thus highlighted the plasticity of the 
NQO1 protein in different ligation states to transmit the effects of single amino acid changes and 
ligand binding. Due to this plasticity, we may anticipate that rare mutations found in cancer cell 
lines (COSMIC) or whole-genome sequence studies (gnomAD) such as p.K240Q would have certain 
effects on NQO1:protein interactions and consequently the stability of its partners. This hypothesis 
awaits to be tested experimentally.  
3. Targeting the chaperone role of NQO1 to inactivate HIF-1: future perspectives 
The chaperone role of NQO1 on HIF-1 has been recently addressed in some detail in relation 
with hypoxia and normoxia  [74]. While hypoxic and normoxic conditions provided somewhat 
different effects, the overall consequence of NQO1:HIF-1 interaction was the stabilization of 
HIF-1 upon interaction. The expression levels of NQO1 consistently modulated the levels of 
HIF-1 likely due to the specific interaction of NQO1 with the ODD domain HIF-1 in the cytosol, 
rather than to changes in HIF-1 mRNA at the transcriptional level  [74]. This interaction enhances 
the intracellular stability of HIF-1 by suppressing its ubiquitination in the cytosol, and thus 
promoting its nuclear import and transcriptional activity  [74]. This chaperone effect is enhanced 
under hypoxic conditions due to increased expression of NQO1  [74, 107]. Intriguingly, the presence 
of the p.P187S polymorphism did not prevent the chaperone action of NQO1, although it is well 
known to reduce NQO1 protein levels due to intracellular destabilization (see Section 2.4). 
We could envision different strategies to disrupt NQO1 interaction with HIF-1 leading to 
increased degradation of the latter:  
i) To prevent PPI by targeting the PP binding site or an allosteric site. We must note that 
allosterism is likely a critical feature for the multifunctionality of both NQO1 (sections 2.3 and 2.4) 
and HIF-1  [145, 146]. Allosterism in HIF-1  is dramatically exemplified by the negative effector 
CITED2, that competes with HIF-1  for the same binding site on CBP/p300 attenuating the 
transcriptional activity of HIF-1  [145, 146] Remarkably, CITED2 and HIF-1  show the same 
binding affinity for CBP/p300, although the former is much more efficient in displacing the latter 
from binary complexes with CBP/p300 due to enhanced HIF-1 release linked to the intrinsic 
disorder of the C-TAD domain. We must note that an important caveat to rational screening for 
ligands is the lack of high-resolution structural models neither for a complex of NQO1 with a partner 
nor for the ODD of HIF-1. There is also no detailed biochemical mapping of the interaction site or 
plausible molecular models. In addition to identifying non-covalent binders, potential, specific 
covalent modifiers should also be considered (cf the cysteine modification of Giardia lamblia triose 
phosphate isomerase by omeprazole which destablises the dimer  [147]). 
ii) A high-throughput screen for ligands that target the formation of the NQO1: HIF-1 complex. 
Both (i) and (ii) would require a rapid, reproducible, robust assay for the interaction in vitro, for 
example labeling of the proteins with a fluorophore and a quencher. A cell-based assay would also 
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be required to test hits from the screen under in vivo conditions, for example proteins labeled with 
FRET donors and acceptors, co-immunoprecipitation or indirectly by measuring amounts of HIF1α. 
Although challenging due to several highly disordered regions in the HIF-1 protein, such screening 
would be still feasible as recently reported for inhibiting PPI in the cancer-associated and 
intrinsically disordered protein NUPR1  [148, 149]. 
iii) To use dicoumarol-like molecules that may target that interaction with lower second-site 
effects  [150, 151, 152]. It must be noted regarding this approach that the effect of NADH or 
dicoumarol have not been tested for the interaction of NQO1 with HIF-1. Many dicoumarol 
analogues that function as NQO1 inhibitors have been reported. It is reasonable to assume that they 
would also antagonize the protein’s interactions with binding partners in a similar way to 
dicoumarol. As such, they represent immediately available compounds, which could be tested for 
their ability to antagonize the NQO1/HIF1α interaction. However they are likely to inhibit or 
antagonize many of NQO1’s functions and may, therefore, cause significant off-target effects. Some 
of these may be undesirable in the context of cancer therapy, e.g. the antagonism of the NQO1/p53 
interaction and consequent down-regulation of p53-mediated apoptosis  [153, 154]. 
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Tables A1 and A2 compile information on known NQO1 substrates, inhibitors and protein partners. 
 
Compound Comments References 
                    Substrates 
Dichlorophenolindolphenol (DCPIP) Non-physiological, but often used in in vitro assays  [155, 156] 
Menadione (Vitamin K3) Reaction occurs in vivo but enzyme likely to play only a minor role in blood clotting  [83, 156] 
Coenzyme Q10 (ubiquinone) NQO1 maintains this, and related compounds, in the reduced form  [157, 158] 
Superoxide ions Likely physiological role in directly combatting oxidative stress in vivo.  [86] 
Fe(III) ions Probably non-physiological  [159] 
Idebenone Important in the metabolism of this drug (a coenzyme Q10 mimic)  [160] 
(3-hydroxymethyl-5-aziridinyl-1-methyl-2-(H-indole-4, 7-indione)-propenol) 
EO9 
Reduction activates this anticancer compound  [161] 
Quinone epoxides Potentially important if members of this group of compounds used as drugs.  [162] 
β-lapachone Futile cycling involving NQO1 results in reduced cellular concentrations of NAD(P)H contributing to 
cell death 
 [163, 164] 
Mitomycin C Reduction activates this akylating cytotoxic drug  [165, 166] 
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Tirapazamine and other heteroaromatic N-oxides Slow reaction.  Superoxide also produced  [167] 
Benzofuroxans Reduction by NQO1 may play a minor role in cytotoxicity  [168] 
Nitroaromatics Reactivity correlates with electrode potential  [169, 170] 
Aminochrome Reaction is important in protection against Parkinson’s Disease and other neurological diseases  [171, 172] 
                         Inhibitors 
Dicoumarol and derivatives thereof High affinity; competes with NAD(P)H; negatively cooperative; often used in experimental studies; 
derivatives may be anticancer lead compounds; dissociates NQO1-p53 complexes resulting in increased 
p53 degradation and inhibition of apoptosis 
 [143, 151, 154, 156, 
173, 174] 
Curcumin May dissociate NQO1-p53 complexes resulting in increased p53 degradation and inhibition of 
apoptosis.  Other studies suggest it may enhance the NQO1-p53 interaction in vivo 
 [175, 176] 
Resveratrol Potent inhibitor of the related protein NQO2; only weakly inhibits NQO1  [177] 
Warfarin NQO1 is a secondary target for this anticoagulant  [174, 178] 
Table A1.  Selected substrates and inhibitors of NQO1. 
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Macromolecule Effect on partner 
stability 
Effect of NAD(P)H Effect of dicoumarol General comments References 
p53 Binds to, and stabilises, the 
full-length protein, protecting it 
from proteasomal degradation 
Increases affinity of 
interaction. 
Antagonises interaction. Interaction promotes p53-mediated apoptosis.  
Dicoumarol down-regulates this by promoting release of 
p53 from NQO1 and consequent degradation of p53. 
 [117, 143, 153, 179, 
180] 
p73α Binds to, and stabilises, the 
full-length protein, protecting it 
from proteasomal degradation. 
Increases affinity of 
interaction; effect not 
observed with NAD+. 
Antagonises interaction. Interaction promotes p73α-mediated apoptosis.  
Dicoumarol down-regulates this by promoting release of 
p73α from NQO1 and consequent degradation of p73α.  
No interaction with p73β which lacks a SAM domain at 
the C-terminus.  The SAM in p73α is responsible for the 
interaction. 
 [78, 117] 
Ornithine 
decarboxylase (ODC) 
NQO1 binds to, and stabilises 
ODC, preventing proteasomal 
degradation 
Not known. Antagonises interaction ODC monomer (inactive) degradation is enhanced by 
binding antizyme 1 (AZ1) which targets the ODC/AZ1 
complex to the proteasome.  NQO1 protects monomeric 
ODC by binding the ODC/AZ1 heterodimer. 
 [181, 182] 
mRNA encoding 
SERPINA1 
(α-1-antitrypsin) 
No effect on stability Not known Not known Does not affect the amount of mRNA, but does enhance the 
translation by binding to 3’-UTR.  This results in more 
protein 
 [114] 
20S proteasomal 
subunit 
Not known No effect Not known NQO1 interacts with the proteasome and negatively 
regulates proteolytic activity.  NQO1-apo is degraded by 
the proteasome. 
 [115] 
HIF-1α NQO1 binds HIF-1α, stabilises 
it and prevent proteasomal 
degradation 
Not known Not known Interaction occurs in cytoplasm. 
NQO1 enhances transcription of HIF-1α regulated genes, 
presumably by increasing the amount of HIF-1α. 
See also main text. 
 [74] 
Hsp70/HSPA4 Interaction most likely occurs Not known Not known NQO1-p.P187S only interacts very weakly.  [183] 
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with newly synthesised NQO1, 
presumably stabilising it and 
assisting folding. 
STUB1/CHIP Not known Not known Not known NQO1 ubiquitination is mediated upon binding to STUB1 
which triggers NQO1 degradation. 
NQO1-p.P187S and apo-NQO1 are degraded efficiently 
by this mechanism. 
STUB1’s TPR domain is required for the interaction. 
 [116, 184] 
c-FOS NQO1 binding to c-FOS 
protects the former from 20S 
proteasomal degradation 
Not known Not known NQO1 localises c-Fos (at least partly) to the cytoplasm.  
Free c-Fos or c-Fos in complex with other transcription 
factors, is localised to the nucleus. 
 [185] 
Bcl2-associated 
Athanogene 3 (BAG3) 
Not known Not known Not known BAG3 regulates the proteasome.  siRNA knockdown of 
BAG3 reduces proteasomal activity. 
 [186] 
ING1B (p33) 
 
NQO1 binds to p33ING1b 
tumour suppressor protecting 
the former from 20S 
proteasomal degradation. 
Increases affinity of 
interaction 
Not known NQO1 binds preferentially to Ser-126 phosphorylated 
p33ING1b.  This phosphorylation is induced by genotoxoic 
stress and increases the in vivo half-life of the protein from 
5.7 h to 16.8 h. 
 [187, 188] 
 
HIV-1 Tat HIV-1 Tat binds to NQO1 
stabilizing the former 
Not known, but assumed to 
promote interaction. 
Antagonises interaction. HIV Rev downregulates NQO1 destabilizing HIV/Tat 
complex and thus resulting in increased Tat degradation. 
Dicoumarol inhibits HIV replication. 
 [138] 
 
eIF4GI 
 
eIF4GI binds to NQO1 leading 
to protection of the former 
against proteasomal 
degradation 
Not known. Antagonises interaction. This interaction modulates mRNA translation.  
Dicoumarol downregulates translation. 
Interaction does not require RNA binding by eIF4GI. 
Oxidative stress reduces the amount of cellular eIF4GI. 
 [189] 
Homocysteine-induced 
endoplasmic reticulum 
Stabilises Herp by protecting it 
from protasomal degradation 
Not known Antagonises interaction Herp is up-regulated in the unfolded protein response 
(UPR).  Herp’s cellular half-life is increased by NQO1. 
 [190, 191] 
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protein (Herp) 
PGC-1α Stabilises this intrinsically 
disordered protein and protects 
it from proteasomal 
degradation. 
Enhances interaction Antagonises interaction Cellular levels of NQO1 and PGC-1α are correlated.  
Stabilisation of PGC-1α by NQO1 leads to induction of 
genes encoding enzymes of gluconeogénesis. 
 [192] 
 
RIL 
(reversion-induced 
LIM domain protein; 
PDLIM4) 
NQO1 binds and stabilises 
unstructured C-terminal región 
of one alternately spliced 
isoform (RILaltCterm) 
protecting it from proteasomal 
degradation. 
Not known Increases RIL proteasomal 
degradation, presumably by 
antagonising RIL/NQO1 
interaction 
RILaltCterm accumulates in response to oxidative stress 
and stimulates actin cytoskeleton rearrangement. 
 [193] 
TAp63γ Stabilises TAp63γ and protects 
it from proteasomal 
degradation. 
Not known Not known NQO1-p.P187S does not interact. 
Interaction occurs in response to genotoxic stress. 
 [194] 
Table A2.  Macromolecular binding partners of NQO1 and effects of ligand binding. 
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